24th Jul 2015 07:01
LONDON (Alliance News) - Shire PLC said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has given a positive opinion for Intuniv in the treatment of attention deficit hyperactivity disorder in children and adolescents.
The European Commission will now consider the committee's positive opinion in making a decision on whether or not to grant marketing authorisation for the product.
"This positive opinion from the CHMP is an important step towards providing physicians with a new therapeutic option for children and adolescents with ADHD," said Head of Research and Development at Shire Philip Vickers in a statement.
Shares in Shire were down 0.5% at 5,610.00 at market open Friday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire